Scott Nicholas Furlan, MD

Pediatric Blood and Marrow Transplant Program

On staff since December 2015

Academic Title: Acting Instructor

"I am driven to improve the therapy of cancer and blood disorders in children not only with thoughtful research, but also by accompanying patients and their families through the daily triumphs and struggles of their journey, one-by-one."

• Biography

  Dr. Scott Furlan studies the biology of blood stem cell transplantation and cellular immunotherapy for people with cancers and other diseases. He is learning how immune cells, such as T cells, behave during and after treatment, and how changes in immune cell behavior affect treatment outcomes. He aims to use what he learns improve transplantation and T-cell therapies for children. Dr. Furlan employs a method called single-cell genomics, which reveals an unprecedented level of detail about the individual cells in a sample. This technique shows him how immune cells respond to new biological surroundings, or microenvironments, throughout treatment. One particular research focus is immune dysfunction in graft-vs.-host disease, in which transplanted donor immune cells attack a patient’s healthy tissues. He also focuses on learning how to improve T-cell therapy and how transplanted donor immune cells affect cancers.

  • Related Pages

  • 

    Scott Nicholas Furlan, M.D.

    Faculty profile for Dr. Scott Furlan. Dr. Furlan studies the biology of blood stem cell transplantation and cellular immunotherapy for people with cancers and other diseases. He is learning how immune cells, such as T cells, behave during and after treatment, and how changes in immune cell behavior affect treatment outcomes.

• Patient Testimonials

  Be the first to recommend Dr. Scott Nicholas Furlan

• Publications

  Other Publications

  • Watkins B, Qayed M, McCracken C, Bratrude B, Betz K, Suessmuth Y, Yu A, Sinclair S, Furlan S, Bosinger S, Tkachev V, Rhodes J, Tumlin AG, Narayan A, Cribbin K, Gillespie S, Gooley TA, Pasquini MC, Hebert K, Kapoor U, Rogatko A, Tighiouart M, Kim S, Bresee C, Choi SW, Davis J, Duncan C, Giller R, Grimley M, Harris AC, Jacobsohn D, Lalefar N, Norkin M, Farhadfar N, Pulsipher MA, Shenoy S, Petrovic A, Schultz KR, Yanik GA, Waller EK, Levine JE, Ferrara JL, Blazar BR, Langston A, Horan JT, Kean LS
    Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD.
    33449816 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021 Jan. 15 : JCO2001086
  • Tkachev V, Kaminski J, Potter EL, Furlan SN, Yu A, Hunt DJ, McGuckin C, Zheng H, Colonna L, Gerdemann U, Carlson J, Hoffman M, Olvera J, English C, Baldessari A, Panoskaltsis-Mortari A, Watkins B, Qayed M, Suessmuth Y, Betz K, Bratrude B, Langston A, Horan JT, Ordovas-Montanes J, Shalek AK, Blazar BR, Roederer M, Kean LS
    Spatiotemporal single-cell profiling reveals that invasive and tissue-resident memory donor CD8+ T cells drive gastrointestinal acute graft-versus-host disease.
    33441422 Science translational medicine, 2021 Jan. 13 : 13(576)
  • Srivastava S, Furlan SN, Jaeger-Ruckstuhl CA, Sarvothama M, Berger C, Smythe KS, Garrison SM, Specht JM, Lee SM, Amezquita RA, Voillet V, Muhunthan V, Yechan-Gunja S, Pillai SPS, Rader C, Houghton AM, Pierce RH, Gottardo R, Maloney DG, Riddell SR
    Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade.
    33357452 Cancer cell, 2020 Dec. 1
  • Thangavelu G, Wang C, Loschi M, Saha A, Osborn M, Furlan SN, Aoyama K, McDonald-Hyman C, Aguilar EG, Janesick AS, Chandraratna RA, Refaeli Y, Panoskaltsis-Mortari A, MacDonald KP, Hill GR, Zeiser R, Maillard I, Serody J, Murphy WJ, Munn DH, Blumberg B, Brown C, Kuchroo VK, Kean LS, Hippen K, Noelle RJ, Blazar BR
    Repurposing a novel anti-cancer RXR agonist to attenuate acute GVHD and maintain graft-versus-leukemia responses.
    32976550 Blood, 2020 Sept. 24
  • Furlan SN, Singh K, Lopez C, Tkachev V, Hunt DJ, Hibbard J, Betz KM, Blazar BR, Trapnell C, Kean LS
    IL-2 enhances ex vivo-expanded regulatory T-cell persistence after adoptive transfer.
    32311015 Blood advances, 2020 April 28 : 4(8)1594-1605 PMCID:PMC7189290
  • Lieberman NAP, DeGolier K, Kovar HM, Davis A, Hoglund V, Stevens J, Winter C, Deutsch G, Furlan SN, Vitanza NA, Leary SES, Crane CA
    Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy.
    30169876 Neuro-oncology, 2019 Jan. 1 : 21(1)83-94 PMCID:PMC6303470
  • Watkins BK, Tkachev V, Furlan SN, Hunt DJ, Betz K, Yu A, Brown M, Poirier N, Zheng HB, Taraseviciute A, Colonna L, Mary C, Blancho G, Soulillou JP, Panoskaltsis-Mortari A, Sharma P, Garcia A, Strobert E, Hamby K, Garrett A, Deane T, Blazar BR, Vanhove B, Kean LS
    CD28 blockade controls T cell activation to prevent graft-versus-host disease in primates.
    30102255 The Journal of clinical investigation, 2018 Aug. 31 : 128(9)3991-4007 PMCID:PMC6118599
  • Pennell CA, Barnum JL, McDonald-Hyman CS, Panoskaltsis-Mortari A, Riddle MJ, Xiong Z, Loschi M, Thangavelu G, Campbell HM, Storlie MD, Refaeli Y, Furlan SN, Jensen MC, Kean LS, Miller JS, Tolar J, Osborn MJ, Blazar BR
    Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice.
    29735365 Molecular therapy : the journal of the American Society of Gene Therapy, 2018 June 6 : 26(6)1423-1434 PMCID:PMC5986973
  • Tkachev V, Furlan SN, Watkins B, Hunt DJ, Zheng HB, Panoskaltsis-Mortari A, Betz K, Brown M, Schell JB, Zeleski K, Yu A, Kirby I, Cooley S, Miller JS, Blazar BR, Casson D, Bland-Ward P, Kean LS
    Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant.
    28931653 Science translational medicine, 2017 Sept. 20 : 9(408) PMCID:PMC5681253
  • Cao J, Packer JS, Ramani V, Cusanovich DA, Huynh C, Daza R, Qiu X, Lee C, Furlan SN, Steemers FJ, Adey A, Waterston RH, Trapnell C, Shendure J
    Comprehensive single-cell transcriptional profiling of a multicellular organism.
    28818938 Science (New York, N.Y.), 2017 Aug. 18 : 357(6352)661-667 PMCID:PMC5894354
  • Furlan SN, Watkins B, Tkachev V, Cooley S, Panoskaltsis-Mortari A, Betz K, Brown M, Hunt DJ, Schell JB, Zeleski K, Yu A, Giver CR, Waller EK, Miller JS, Blazar BR, Kean LS
    Systems analysis uncovers inflammatory Th/Tc17-driven modules during acute GVHD in monkey and human T cells.
    27758873 Blood, 2016 Nov. 24 : 128(21)2568-2579 PMCID:PMC5123196
  • Saha A, O'Connor RS, Thangavelu G, Lovitch SB, Dandamudi DB, Wilson CB, Vincent BG, Tkachev V, Pawlicki JM, Furlan SN, Kean LS, Aoyama K, Taylor PA, Panoskaltsis-Mortari A, Foncea R, Ranganathan P, Devine SM, Burrill JS, Guo L, Sacristan C, Snyder NW, Blair IA, Milone MC, Dustin ML, Riley JL, Bernlohr DA, Murphy WJ, Fife BT, Munn DH, Miller JS, Serody JS, Freeman GJ, Sharpe AH, Turka LA, Blazar BR
    Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality.
    27294527 The Journal of clinical investigation, 2016 July 1 : 126(7)2642-60 PMCID:PMC4922691
  • Furlan SN, Watkins B, Tkachev V, Flynn R, Cooley S, Ramakrishnan S, Singh K, Giver C, Hamby K, Stempora L, Garrett A, Chen J, Betz KM, Ziegler CG, Tharp GK, Bosinger SE, Promislow DE, Miller JS, Waller EK, Blazar BR, Kean LS
    Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention.
    26606970 Science translational medicine, 2015 Nov. 25 : 7(315)315ra191 PMCID:PMC4876606
  • Furlan SN, Watkins B, Tkachev V, Flynn R, Cooley S, Ramakrishnan S, Singh K, Giver C, Hamby K, Stempora L, Garrett A, Chen J, Betz KM, Ziegler CG, Tharp GK, Bosinger SE, Promislow DE, Miller JS, Waller EK, Blazar BR, Kean LS
    Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention.
    26606970 Science translational medicine, 2015 Nov. 25 : 7(315)315ra191
  • Furlan SN, Mandraju R, Brewer T, Roybal K, Troutman TD, Hu W, Palm NW, Unni A, Pasare C
    Enhancement of anti-tumor CD8 immunity by IgG1-mediated targeting of Fc receptors.
    24284965 mAbs, 2014 Jan. : 6(1)108-18 PMCID:PMC3929435
  • Furlan SN, Mandraju R, Brewer T, Roybal K, Troutman TD, Hu W, Palm NW, Unni A, Pasare C
    Enhancement of anti-tumor CD8 immunity by IgG1-mediated targeting of Fc receptors.
    24284965 mAbs, 2014 Jan. : 6(1)108-18 PMCID:PMC3929435

  ---

  Show More Hide